- Markets
- Chemicals
- SHIVALIK
SHIVALIK
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Shivalik Rasayan Says US FDA Approved API Facility At Dahej
Oct 3 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
US FDA APPROVED API FACILITY OF SHIVALIK RASAYAN AT DAHEJ
US FDA RELEASED ESTABLISHMENT INSPECTION REPORT FOR DAHEJ INSPECTION
Source text for Eikon: ID:nBSE6BVxKL
Further company coverage: SIVA.NS
(([email protected];;))
Oct 3 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
US FDA APPROVED API FACILITY OF SHIVALIK RASAYAN AT DAHEJ
US FDA RELEASED ESTABLISHMENT INSPECTION REPORT FOR DAHEJ INSPECTION
Source text for Eikon: ID:nBSE6BVxKL
Further company coverage: SIVA.NS
(([email protected];;))
India's Shivalik Rasayan up as U.S. FDA completes inspection at Gujarat factory
** Shares of agrochemicals and active pharma ingredients (API) maker Shivalik Rasayan SIVA.NS rise 5% to 590.35 rupees
** Co says U.S. Food and Drug Administration completed inspection at its Dahej factory, Gujarat, with seven procedural observations
** Shares down 20% YTD after falling 2.6% in 2023
(Reporting by Sethuraman NR in Bengaluru)
(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))
** Shares of agrochemicals and active pharma ingredients (API) maker Shivalik Rasayan SIVA.NS rise 5% to 590.35 rupees
** Co says U.S. Food and Drug Administration completed inspection at its Dahej factory, Gujarat, with seven procedural observations
** Shares down 20% YTD after falling 2.6% in 2023
(Reporting by Sethuraman NR in Bengaluru)
(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))
Shivalik Rasayan Says US FDA Completes Inspection At API Facility At Dahej Unit
April 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - COMPLETION OF US FDA INSPECTION AT API FACILITY OF SHIVALIK RASAYAN LIMITED AT DAHEJ UNIT
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
Source text for Eikon: ID:nBSE6fcsV1
Further company coverage: SIVA.NS
(([email protected];;))
April 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - COMPLETION OF US FDA INSPECTION AT API FACILITY OF SHIVALIK RASAYAN LIMITED AT DAHEJ UNIT
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
Source text for Eikon: ID:nBSE6fcsV1
Further company coverage: SIVA.NS
(([email protected];;))
Shivalik Rasayan Says Approvals To Construct Rg-4 At Dahej Unit-I Received From GIDC
March 26 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
APPROVALS TO CONSTRUCT RG-4 AT DAHEJ UNIT-I ARE RECEIVED FROM GIDC
VENDORS/ CONTRACTORS ARE FINALISED AND CONSTRUCTION ACTIVITIES STARTED
Source text for Eikon: ID:nBSEb4Ll6P
Further company coverage: SIVA.NS
(([email protected];))
March 26 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
APPROVALS TO CONSTRUCT RG-4 AT DAHEJ UNIT-I ARE RECEIVED FROM GIDC
VENDORS/ CONTRACTORS ARE FINALISED AND CONSTRUCTION ACTIVITIES STARTED
Source text for Eikon: ID:nBSEb4Ll6P
Further company coverage: SIVA.NS
(([email protected];))
Shivalik Rasayan Says All Required Licenses To Start Manufacturing At Newly Build Agro-Chemical Plant Received
March 7 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ALL REQUIRED LICENSES TO START MANUFACTURING AT NEWLY BUILD AGRO-CHEMICAL PLANT RECEIVED NOW
TRIAL BATCHES FOR P.G. EASTER, AZOXYSTROBIN, PYMETROZINE HAS BEEN TAKEN SUCCESSFULLY
COMMERCIAL PRODUCTIONS SHALL START FROM APRIL, 2024
Source text for Eikon: ID:nBSE1yXL5
Further company coverage: SIVA.NS
(([email protected];))
March 7 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ALL REQUIRED LICENSES TO START MANUFACTURING AT NEWLY BUILD AGRO-CHEMICAL PLANT RECEIVED NOW
TRIAL BATCHES FOR P.G. EASTER, AZOXYSTROBIN, PYMETROZINE HAS BEEN TAKEN SUCCESSFULLY
COMMERCIAL PRODUCTIONS SHALL START FROM APRIL, 2024
Source text for Eikon: ID:nBSE1yXL5
Further company coverage: SIVA.NS
(([email protected];))
Shivalik Rasayan Received Certificate Of Suitability For Pirfenidone From European Directorate For Quality Of Medicine & Healthcare
Jan 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RECEIVED CERTIFICATE OF SUITABILITY FOR PIRFENIDONE FROM EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINE & HEALTHCARE
Further company coverage: SIVA.NS
(([email protected];))
Jan 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RECEIVED CERTIFICATE OF SUITABILITY FOR PIRFENIDONE FROM EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINE & HEALTHCARE
Further company coverage: SIVA.NS
(([email protected];))
Shivalik Rasayan Re-Appoints Dr. Vimal Kumar Shrawat As Managing Director
Aug 8 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RE-APPOINTS DR. VIMAL KUMAR SHRAWAT AS MANAGING DIRECTOR
Source text for Eikon: ID:nNSE1HL4BC
Further company coverage: SIVA.NS
(([email protected];))
Aug 8 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RE-APPOINTS DR. VIMAL KUMAR SHRAWAT AS MANAGING DIRECTOR
Source text for Eikon: ID:nNSE1HL4BC
Further company coverage: SIVA.NS
(([email protected];))
India's Shivalik Rasayan rises after China regulator permits drug evaluation
** Shares of Shivalik Rasayan SIVA.NS rise as much as 5.2% to 787.55 rupees, biggest intraday pct gain since June 16
** Active pharma ingredient (API)-maker says Centre for Drug Evaluation, China, has permitted evaluation of its anti-leukemia API Bendamustine
** Process of evaluation and approval underway - SIVA
** Trading volume at ~11,300 shares, slightly below the 30-day avg of ~12,800 shares as of 12:10 p.m. IST
** Stock last down ~1% YTD
(Reporting by Biplob Kumar Das in Bengaluru)
** Shares of Shivalik Rasayan SIVA.NS rise as much as 5.2% to 787.55 rupees, biggest intraday pct gain since June 16
** Active pharma ingredient (API)-maker says Centre for Drug Evaluation, China, has permitted evaluation of its anti-leukemia API Bendamustine
** Process of evaluation and approval underway - SIVA
** Trading volume at ~11,300 shares, slightly below the 30-day avg of ~12,800 shares as of 12:10 p.m. IST
** Stock last down ~1% YTD
(Reporting by Biplob Kumar Das in Bengaluru)
Shivalik Rasayan Issued LOA To Medicamen Biotech
July 19 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ISSUED LOA TO MEDICAMEN BIOTECH, TO USE DMF GRADE BORTEZOMIB API FOR FORMULATION OF BORTEZOMIB INJECTION 3.5MG/ VIAL
Source text for Eikon: ID:nBSE219bhg
Further company coverage: SIVA.NS
(([email protected];;))
July 19 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ISSUED LOA TO MEDICAMEN BIOTECH, TO USE DMF GRADE BORTEZOMIB API FOR FORMULATION OF BORTEZOMIB INJECTION 3.5MG/ VIAL
Source text for Eikon: ID:nBSE219bhg
Further company coverage: SIVA.NS
(([email protected];;))
Shivalik Rasayan To Consider Proposal For Raising Funds
May 30 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - TO CONSIDER PROPOSAL FOR RAISING FUNDS
Source text for Eikon: ID:nBSEDksnd
Further company coverage: SIVA.NS
(([email protected];))
May 30 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - TO CONSIDER PROPOSAL FOR RAISING FUNDS
Source text for Eikon: ID:nBSEDksnd
Further company coverage: SIVA.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Bonus
Split
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Shivalik Rasayan do?
Established in 1981, Shivalik Rasayan Ltd. (SRL) is a leading manufacturer of international quality Malathion Technical and Dimethoate Technical, well established in Indian and foreign markets.
Who are the competitors of Shivalik Rasayan?
Shivalik Rasayan major competitors are Wanbury, Kwality Pharma, Anuh Pharma, Lincoln Pharma, Sakar Healthcare, Bharat Parenterals, Prevest Denpro. Market Cap of Shivalik Rasayan is ₹957 Crs. While the median market cap of its peers are ₹849 Crs.
Is Shivalik Rasayan financially stable compared to its competitors?
Shivalik Rasayan seems to be less financially stable compared to its competitors. Altman Z score of Shivalik Rasayan is 3.43 and is ranked 7 out of its 8 competitors.
Does Shivalik Rasayan pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Shivalik Rasayan latest dividend payout ratio is 6.12% and 3yr average dividend payout ratio is 4.15%
How has Shivalik Rasayan allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Shivalik Rasayan balance sheet?
Balance sheet of Shivalik Rasayan is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Shivalik Rasayan improving?
The profit is oscillating. The profit of Shivalik Rasayan is ₹19.83 Crs for TTM, ₹12.72 Crs for Mar 2024 and ₹20.75 Crs for Mar 2023.
Is the debt of Shivalik Rasayan increasing or decreasing?
Yes, The debt of Shivalik Rasayan is increasing. Latest debt of Shivalik Rasayan is ₹59.7 Crs as of Sep-24. This is greater than Mar-24 when it was ₹10.54 Crs.
Is Shivalik Rasayan stock expensive?
Shivalik Rasayan is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Shivalik Rasayan is 58.89, while 3 year average PE is 58.21. Also latest EV/EBITDA of Shivalik Rasayan is 23.25 while 3yr average is 25.92.
Has the share price of Shivalik Rasayan grown faster than its competition?
Shivalik Rasayan has given lower returns compared to its competitors. Shivalik Rasayan has grown at ~-14.29% over the last 3yrs while peers have grown at a median rate of 20.17%
Is the promoter bullish about Shivalik Rasayan?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Shivalik Rasayan is 47.37% and last quarter promoter holding is 47.95%
Are mutual funds buying/selling Shivalik Rasayan?
There is Insufficient data to gauge this.